Memphasys Limited (ASX: MEM) reported a significant revenue jump driven by commercialisation of its Felix™ System, narrowing its net loss to $4.1 million for the year ended 30 June 2026.
- Felix™ System sales jump from $3.7K to $273.8K
- Net loss improves to $4.1 million from $5.0 million
- Cash position strengthens to $1.18 million
- Largest Felix™ contract secured with Monash IVF
- Board refresh and key executive transitions
Felix™ Commercialisation Drives Revenue Growth
Memphasys Limited (ASX:MEM) has marked a pivotal year in its commercial journey, with sales of its patented Felix™ System soaring to $273,793 in FY2026, up from a mere $3,700 the previous year. This leap reflects the transition from pilot sales to multiple contracted commercial agreements spanning Australia, Europe, the UK, MENA, India, Japan, Vietnam and Thailand. The company’s targeted commercial roll-out strategy is clearly bearing fruit, underpinning a 7,300% increase in revenue.
Despite this surge, Memphasys remains unprofitable, reporting a net loss of $4.1 million, an 18% improvement from the $5.0 million loss in FY2025. The narrowing loss is attributed to both increased sales and disciplined cost management, including a $315,000 reduction in research and development expenses as the company prioritises Felix™ commercialisation over earlier-stage projects like RoXsta™.
Balance Sheet Strengthened with Cash Boost and Capital Raises
Memphasys closed FY2026 with cash and cash equivalents of $1.18 million, a substantial increase from $298,302 at the prior year-end. This improvement was supported by net cash inflows of $3.37 million from financing activities, including a $1.2 million placement in June 2026 aimed at funding manufacturing scale-up and inventory build for Felix™ cartridges.
Net assets stood at $4.21 million, underpinned by intangible assets of $8.8 million primarily representing capitalised development costs for Felix™. However, the company continues to operate with a working capital deficit of $4.81 million, reflecting ongoing investment in commercialisation and operations.
Key Contracts and Regulatory Progress Fuel Confidence
FY2026 was highlighted by the execution of Memphasys’s largest Felix™ supply agreement with Monash IVF Group Ltd, covering 22 clinics and signalling strong market acceptance in Australia. The company’s footprint expanded in Southeast Asia with exclusive distribution agreements in Vietnam and Thailand, collectively valued at nearly A$1 million. These deals are expected to generate recurring revenue streams, contingent on regulatory approvals which are anticipated imminently in Vietnam, Turkey, and India.
The company also secured critical regulatory milestones including CE Mark in December 2025 and TGA/ARTG registration in Australia in February 2026, facilitating broader market access and underpinning commercial discussions in Europe and the UK.
Leadership Changes and Governance Updates
Memphasys underwent significant board and executive transitions during the year. David Tasker was appointed Non-Executive Chairman in May 2026, bringing extensive investor relations expertise and a substantial personal shareholding. Other key appointments included Marjan Mikel and Mathew Watkins as Non-Executive Directors, while former CEO Dr David Ali stepped down at year-end. These changes reflect a strategic refresh aligned with the company’s shift toward commercial execution.
The company maintains a disciplined remuneration framework balancing fixed and performance-linked incentives, with 42 million options issued to directors and key management personnel during the year, supporting alignment with shareholder interests.
Auditor Flags Going Concern Uncertainty Amid Growth
BDO Audit Pty Ltd issued a clean audit opinion but highlighted a material uncertainty related to Memphasys’s ability to continue as a going concern. The company’s financial report notes reliance on securing additional funding, deferral of convertible note repayments (extended to June 2027), and successful commercialisation of Felix™ to achieve sustainable cash flow. Directors express confidence in these factors, citing recent capital raises, contract wins, and regulatory approvals as evidence of a viable path forward.
Investors should note that while commercial momentum is building, risks remain around market acceptance, regulatory hurdles, and funding requirements. The company’s concentrated reliance on Felix™ underscores the importance of its successful global rollout.
Bottom Line?
Memphasys’s FY26 results reveal tangible commercial progress with Felix™ sales ramping up, yet the path to profitability hinges on sustaining growth and managing funding risks.
Questions in the middle?
- Will upcoming regulatory approvals in Vietnam, Turkey, and India translate into meaningful revenue growth?
- How will Memphasys manage working capital deficits while scaling manufacturing and sales?
- What impact will recent board and executive changes have on execution of the commercialisation strategy?